Peroxisome proliferator-activated receptor γ in diabetes and metabolism

被引：387

作者：

Rangwala, SM

Lazar, MA ^{[1
]}

机构：

[1] Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA

[2] Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2004年 / 25卷 / 06期

关键词：

D O I：

10.1016/j.tips.2004.03.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The peroxisome proliferator-activated receptor gamma (PPAR-gamma) has been the focus of intense research during the past decade because ligands for this receptor have emerged as potent insulin sensitizers used in the treatment of type 2 diabetes. Recent advances include the discovery of novel genes that are regulated by PPAR-gamma, which helps explain how activation of this adipocyte-predominant transcription factor regulates glucose and lipid homeostasis. Increased levels of circulating free fatty acids and lipid accumulation in non-adipose tissue have been implicated in the development of insulin resistance. This situation is improved by PPAR-gamma ligands, which promote fatty acid storage in fat depots and regulate the expression of adipocyte-secreted hormones that impact on glucose homeostasis. The net result of the pleiotropic effects of PPAR-gamma ligands is improvement of insulin sensitivity, although undesired side-effects limit the utility of this therapy. It might be possible to dissociate the anti-diabetic and adverse effects through selective modulation of PPAR-gamma activity.

引用

页码：331 / 336

页数：6

共 76 条

[11] Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma [J].